[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SI2097078T1 - Nanodelci paklitaksela in albumina v kombinaciji z bevacizumabom proti raku - Google Patents

Nanodelci paklitaksela in albumina v kombinaciji z bevacizumabom proti raku

Info

Publication number
SI2097078T1
SI2097078T1 SI200731475T SI200731475T SI2097078T1 SI 2097078 T1 SI2097078 T1 SI 2097078T1 SI 200731475 T SI200731475 T SI 200731475T SI 200731475 T SI200731475 T SI 200731475T SI 2097078 T1 SI2097078 T1 SI 2097078T1
Authority
SI
Slovenia
Prior art keywords
paclitaxel
nanoparticles
albumin
combination
against cancer
Prior art date
Application number
SI200731475T
Other languages
English (en)
Inventor
Neil P. Desai
Patrick Soon-Shiong
Original Assignee
Abraxis Bioscience, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience, Llc filed Critical Abraxis Bioscience, Llc
Publication of SI2097078T1 publication Critical patent/SI2097078T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI200731475T 2006-11-06 2007-11-06 Nanodelci paklitaksela in albumina v kombinaciji z bevacizumabom proti raku SI2097078T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/594,417 US20070166388A1 (en) 2005-02-18 2006-11-06 Combinations and modes of administration of therapeutic agents and combination therapy
PCT/US2007/023446 WO2008057562A1 (en) 2006-11-06 2007-11-06 Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
EP07839976.3A EP2097078B1 (en) 2006-11-06 2007-11-06 Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer

Publications (1)

Publication Number Publication Date
SI2097078T1 true SI2097078T1 (sl) 2014-07-31

Family

ID=39111840

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200731475T SI2097078T1 (sl) 2006-11-06 2007-11-06 Nanodelci paklitaksela in albumina v kombinaciji z bevacizumabom proti raku
SI200731795A SI2481405T1 (sl) 2006-11-06 2007-11-06 Nanodelci paklitaksela in albumina v kombinaciji z bevacizumabom proti raku

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200731795A SI2481405T1 (sl) 2006-11-06 2007-11-06 Nanodelci paklitaksela in albumina v kombinaciji z bevacizumabom proti raku

Country Status (23)

Country Link
US (1) US20070166388A1 (sl)
EP (3) EP2097078B1 (sl)
JP (3) JP5931323B2 (sl)
KR (4) KR20180012339A (sl)
CN (2) CN101573108A (sl)
AU (1) AU2007317859B2 (sl)
BR (1) BRPI0718528A2 (sl)
CA (1) CA2668607A1 (sl)
CY (2) CY1115271T1 (sl)
DK (2) DK2097078T3 (sl)
ES (2) ES2576289T3 (sl)
HK (1) HK1173976A1 (sl)
HU (1) HUE028472T2 (sl)
IL (2) IL198576A (sl)
MX (1) MX2009004803A (sl)
NO (1) NO343908B1 (sl)
NZ (1) NZ576856A (sl)
PL (2) PL2097078T3 (sl)
PT (2) PT2481405E (sl)
RU (2) RU2009121568A (sl)
SI (2) SI2097078T1 (sl)
WO (1) WO2008057562A1 (sl)
ZA (1) ZA200903132B (sl)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070122465A1 (en) * 1993-02-22 2007-05-31 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
ES2435944T3 (es) * 1997-06-27 2013-12-26 Abraxis Bioscience, Llc Nuevas formulaciones de agentes farmacológicos, métodos para su preparación y métodos para su uso
KR20200083657A (ko) 2002-12-09 2020-07-08 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
US8735394B2 (en) * 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
DK1853250T3 (da) * 2005-02-18 2012-01-23 Abraxis Bioscience Llc Kombinationer og måder til indgivelse af terapeutiske midler og kombinationsterapi
KR101457834B1 (ko) * 2005-08-31 2014-11-05 아브락시스 바이오사이언스, 엘엘씨 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조 방법
BRPI0615265A8 (pt) * 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
EP2041283B1 (en) * 2006-06-26 2013-02-20 The University Of British Columbia Secreted protein acidic and rich in cysteine (sparc) as chemotherapeutic sensitizers
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
KR20090095571A (ko) * 2006-11-01 2009-09-09 조지 매이슨 인털렉춸 프로퍼티즈, 인코퍼레이티드 암을 검출하고 조절하기 위한 방법
CN101605535A (zh) 2006-12-14 2009-12-16 阿布拉科斯生物科学有限公司 用包含紫杉烷的纳米颗粒基于激素受体状态治疗乳腺癌
HUE039497T2 (hu) * 2007-03-07 2019-01-28 Abraxis Bioscience Llc Rapamicin rákellenes szert és albumint tartalmazó nanorészecske
CA2686736A1 (en) * 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Nanoparticle compositions comprising rapamycin for treating pulmonary hypertension
EP2155188B1 (en) * 2007-06-01 2013-10-09 Abraxis BioScience, LLC Methods and compositions for treating recurrent cancer
WO2009002425A2 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without tween 80
ITMI20080284A1 (it) * 2008-02-22 2009-08-23 Indena Spa Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono
AU2009234127B2 (en) * 2008-04-10 2015-04-30 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
WO2010003057A2 (en) 2008-07-03 2010-01-07 Mayo Foundation For Medical Education And Research Treating cancer
EP2153821A1 (en) * 2008-08-06 2010-02-17 BioAlliance Pharma Oral formulations of camptothecin derivatives
US8546433B2 (en) * 2009-01-16 2013-10-01 Rigel Pharmaceuticals, Inc. Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
WO2010105172A1 (en) * 2009-03-13 2010-09-16 Abraxis Bioscience, Llc Combination therapy with thiocolchicine derivatives
SMT201900751T1 (it) 2009-04-15 2020-03-13 Abraxis Bioscience Llc Composizioni nanoparticellari prive di prioni e metodi
MX2012000383A (es) * 2009-07-07 2012-06-01 Normoxys Inc Método para reducir la resistencia a terapias multidroga utilizando tripirofosfato de inositol.
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
CA2930248A1 (en) * 2010-02-23 2011-09-01 Genentech, Inc. Anti-angiogenesis therapy for the treatment of ovarian cancer
EP2552438B1 (en) 2010-03-26 2016-05-11 Abraxis BioScience, LLC Methods of treatment of hepatocellular carcinoma
AU2011232862B2 (en) * 2010-03-29 2016-03-03 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
CA3087813A1 (en) * 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of treating cancer
CN106924219A (zh) 2010-06-04 2017-07-07 阿布拉科斯生物科学有限公司 治疗胰腺癌的方法
NZ707377A (en) * 2010-06-07 2015-09-25 Abraxis Bioscience Llc Combination therapy methods for treating proliferative diseases
US20120121510A1 (en) * 2010-11-11 2012-05-17 Brem Rachel F Localized therapy following breast cancer surgery
US20130323265A1 (en) * 2010-11-15 2013-12-05 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with dll4 antagonists
US9427477B2 (en) 2011-05-09 2016-08-30 Mayo Foundation For Medical Education And Research Cancer treatments
EP2773322A1 (en) 2011-11-01 2014-09-10 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
WO2013085902A1 (en) 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
CA2858593C (en) 2011-12-14 2022-05-17 Abraxis Bioscience, Llc Use of polymeric excipients for lyophilization or freezing of particles
JP6563197B2 (ja) 2012-03-13 2019-08-21 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 卵巣癌の治療のための併用療法
EP2903610B1 (en) 2012-10-01 2021-11-03 Mayo Foundation For Medical Education And Research Cancer treatments
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
BR112015019064A8 (pt) * 2013-02-11 2019-11-12 Abraxis Bioscience Llc uso de uma composição compreendendo nanopartículas compreendendo paclitaxel e uma albumina para o tratamento de melanoma e kit
EP2968254B1 (en) 2013-03-12 2020-04-22 Abraxis BioScience, LLC Methods of treating lung cancer
CA2903548A1 (en) 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer
US10842969B2 (en) 2013-10-25 2020-11-24 Mercator Medsystems, Inc. Systems and methods of treating malacia by local delivery of hydrogel to augment tissue
WO2015134543A1 (en) * 2014-03-05 2015-09-11 Sorrento Therapeutics, Inc. Pharmacokinetically equivalent nanoparticle compositions
EP2924022A1 (en) * 2014-03-27 2015-09-30 INDENA S.p.A. Amorphous form of a thiocolchicine derivative
KR20170020371A (ko) 2014-06-16 2017-02-22 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 골수종의 치료
US20150359810A1 (en) 2014-06-17 2015-12-17 Celgene Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
CN104434808A (zh) * 2014-07-03 2015-03-25 石药集团中奇制药技术（石家庄）有限公司 一种治疗性纳米粒子及其制备方法
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
JP2017527531A (ja) * 2014-10-06 2017-09-21 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ 担体および抗体からなる組成物およびその製造および使用方法
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
JP6987644B2 (ja) 2015-06-29 2022-01-05 アブラクシス バイオサイエンス， エルエルシー 類上皮細胞腫瘍を処置する方法
WO2017176265A1 (en) * 2016-04-06 2017-10-12 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
EP3337823A4 (en) * 2015-08-18 2019-05-08 Mayo Foundation for Medical Education and Research SUPPORTING BIN COMPOSITIONS AND METHOD FOR THE PRODUCTION AND USE THEREOF
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
CN105288639A (zh) * 2015-11-23 2016-02-03 中国药科大学 一种载阿霉素的主动靶向白蛋白纳米载体的制备及其应用
EP3399861A4 (en) 2016-01-07 2019-08-07 Mayo Foundation for Medical Education and Research METHOD FOR THE TREATMENT OF CANCER WITH INTERFERON
AU2017217881B2 (en) * 2016-02-12 2022-11-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
WO2017165440A1 (en) * 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
WO2017165439A1 (en) * 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
WO2018027205A1 (en) * 2016-08-05 2018-02-08 Mayo Foundation For Medical Education And Research Modified antibody-albumin nanoparticle complexes for cancer treatment
JP6956091B2 (ja) * 2016-08-26 2021-10-27 哲治 奥野 微小ナノ化薬剤およびその利用
US11160876B2 (en) 2016-09-01 2021-11-02 Mayo Foundation For Medical Education And Research Methods and compositions for targeting t-cell cancers
EP3506942B1 (en) 2016-09-01 2022-11-16 Mayo Foundation for Medical Education and Research Carrier-pd-l1 binding agent compositions for treating cancers
CA3035655A1 (en) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Methods of treating pd-l1 expressing cancer
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
WO2018048958A1 (en) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
CN106310291A (zh) * 2016-09-14 2017-01-11 东南大学 主动靶向抗肿瘤纳米药物及其制备方法和应用
HUE058289T2 (hu) 2016-10-27 2022-07-28 Celgene Quanticel Res Inc Brómdomén és extraterminális protein inhibitor kombinációs terápia
EP3532077A4 (en) * 2016-10-28 2020-06-10 Nant Holdings IP, LLC Avatar dendritic cells: the neoantigen natural killer t-cell chemo immuno radiation composition inducing immunogenic cell death
CA3081750A1 (en) 2017-11-06 2019-05-09 Rapt Therapeutics, Inc. Anticancer agents
WO2019104042A1 (en) * 2017-11-21 2019-05-31 University Of Iowa Research Foundation Synthetically lethal nanoparticles for treatment of cancers
MX2020006042A (es) * 2017-12-19 2020-10-20 Abraxis Bioscience Llc Metodos de tratamiento de cancer de colon usando terapia combinada de inhibidor del objetivo mamifero de la rapamicina (mtor) en nanoparticulas.
WO2019147944A1 (en) 2018-01-26 2019-08-01 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disordres using anti-vegf agents
KR20200135410A (ko) 2018-03-20 2020-12-02 아브락시스 바이오사이언스, 엘엘씨 mTOR 억제제 및 알부민의 나노입자의 투여를 통한 중추 신경계 장애의 치료 방법
US11497737B2 (en) 2019-10-28 2022-11-15 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin
JP2023502501A (ja) 2019-11-25 2023-01-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 眼内血管新生のための長時間作用型ｖｅｇｆ阻害剤
KR102263606B1 (ko) 2020-02-11 2021-06-10 충북대학교 산학협력단 파클리탁셀과 알피늄이소플라본을 함유한 나노 마이셀, 이의 제조방법 및 이의 용도

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470571A (en) 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
IL98528A0 (en) 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
EP0531472B1 (en) 1991-03-06 2003-08-13 MERCK PATENT GmbH Humanized monoclonal antibodies
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
CA2192470A1 (en) 1994-01-14 1995-07-20 Paul A. Brown Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
DK1325932T5 (da) 1997-04-07 2005-10-03 Genentech Inc Anti-VEGF antistoffer
CN1125651C (zh) 1998-04-16 2003-10-29 欧维塔有限公司 新颖的、含有存在于大高良姜中的芳族化合物与萜类化合物的协同组合物
CA2369740A1 (en) 1999-04-22 2000-11-02 American Biosciences, Inc. Long term administration of pharmacologically active agents
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
US20040143004A1 (en) 2002-02-26 2004-07-22 Joseph Fargnoli Metronomic dosing of taxanes
KR20200083657A (ko) 2002-12-09 2020-07-08 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
KR20120104408A (ko) 2003-05-30 2012-09-20 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
EA200600495A1 (ru) * 2003-09-23 2006-10-27 Новартис Аг Комбинация ингибитора vegf рецептора с химиотерапевтическим агентом
US20060003931A1 (en) 2004-05-06 2006-01-05 Genentech, Inc. Crystal structure of the hepatocyte growth factor and methods of use
EP2286844A3 (en) 2004-06-01 2012-08-22 Genentech, Inc. Antibody-drug conjugates and methods
CN102512675A (zh) 2004-06-04 2012-06-27 健泰科生物技术公司 用于治疗多发性硬化的方法
SV2006002143A (es) 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
US8772269B2 (en) * 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
JP5475234B2 (ja) * 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド 医薬化合物
DK1853250T3 (da) * 2005-02-18 2012-01-23 Abraxis Bioscience Llc Kombinationer og måder til indgivelse af terapeutiske midler og kombinationsterapi
CA2599301A1 (en) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. Novel use of sulfonamide compound in combination with angiogenesis inhibitor
BRPI0615265A8 (pt) * 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
KR101457834B1 (ko) * 2005-08-31 2014-11-05 아브락시스 바이오사이언스, 엘엘씨 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조 방법

Also Published As

Publication number Publication date
EP2481405A1 (en) 2012-08-01
PT2481405E (pt) 2016-06-08
PL2097078T3 (pl) 2014-09-30
KR20170016017A (ko) 2017-02-10
PT2097078E (pt) 2014-07-25
MX2009004803A (es) 2009-07-09
EP2097078A1 (en) 2009-09-09
KR20180012339A (ko) 2018-02-05
DK2481405T3 (en) 2016-06-06
JP2010509331A (ja) 2010-03-25
HK1173976A1 (zh) 2013-05-31
NO20092179L (no) 2009-08-06
CY1117725T1 (el) 2017-05-17
EP2097078B1 (en) 2014-04-16
NO343908B1 (no) 2019-07-01
KR101857142B1 (ko) 2018-05-14
CN101573108A (zh) 2009-11-04
RU2009121568A (ru) 2010-12-20
ZA200903132B (en) 2010-08-25
US20070166388A1 (en) 2007-07-19
ES2576289T3 (es) 2016-07-06
CN104940929A (zh) 2015-09-30
AU2007317859A1 (en) 2008-05-15
RU2673805C2 (ru) 2018-11-30
IL244390A (en) 2017-04-30
IL244390A0 (en) 2016-04-21
KR20150065957A (ko) 2015-06-15
EP2481405B1 (en) 2016-03-23
BRPI0718528A2 (pt) 2013-11-19
WO2008057562A1 (en) 2008-05-15
JP2016014073A (ja) 2016-01-28
JP2014043454A (ja) 2014-03-13
IL198576A (en) 2016-12-29
PL2481405T3 (pl) 2016-09-30
KR20090087906A (ko) 2009-08-18
RU2013149282A (ru) 2015-05-10
CA2668607A1 (en) 2008-05-15
JP5931323B2 (ja) 2016-06-08
IL198576A0 (en) 2010-02-17
EP3108885A1 (en) 2016-12-28
NZ576856A (en) 2012-06-29
ES2469716T3 (es) 2014-06-18
SI2481405T1 (sl) 2016-08-31
HUE028472T2 (en) 2016-12-28
DK2097078T3 (da) 2014-05-12
AU2007317859B2 (en) 2013-07-25
CY1115271T1 (el) 2017-01-04

Similar Documents

Publication Publication Date Title
IL244390A0 (en) Nonparticles of paclitaxel and albumin in combination with bevacizumab against cancer
HRP20181217T1 (hr) Nanočestica koja kao antikancerogeno sredstvo sadrži rapamicin i albumin
IL247617A0 (en) Peptide nanoparticles and their uses
HK1136822A1 (en) Therapeutic compounds and their use in cancer
HK1215683A1 (zh) 抗葉酸藥在癌症治療中的聯合應用
ZA201008045B (en) Nanoparticle formulations and uses thereof
EP2048189A4 (en) ALUMINUM OXIDE NANOPARTICLE WITH COATED SURFACE AND RESIN COMPOSITION THEREOF
HUE050370T2 (hu) Rosszindulatú daganat kezelése elektromágneses mezõ és rákellenes szerek kombinációjával
ZA200902161B (en) Antiobodies and immunoconjugates and uses therefor
GB2461473B (en) Nanoparticles and fabrication thereof
IL209361A0 (en) Combination therapy with pm00104 and another antitumor agent
IL242077B (en) Sp–1 complexes with nanoparticles and their use
GB0503216D0 (en) Nanoparticles and uses there of
GB0603433D0 (en) Nanoparticle and nanocomposite films